Phase III of Bellerophon's INOpulse for PAH stopped for futility

Bellerophon Therapeutics Inc. (NASDAQ:BLPH) said a DMC recommended stopping for futility the Phase III INOvation-1 trial of INOpulse to treat pulmonary arterial hypertension (PAH).

A prespecified interim

Read the full 266 word article

User Sign In